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Purpose: To assess the long-term impact of adding bevacizumab to adjuvant 
chemotherapy for early triple-negative breast cancer (TNBC). 
Methods: Patients eligible for the open-label randomized phase III BEATRICE trial 
had centrally confirmed triple-negative operable primary invasive breast cancer 
(pT1a–pT3). Investigators selected anthracycline- and/or taxane-based 
chemotherapy for each patient. After definitive surgery, patients were randomized 
1:1 to receive ≥4 cycles of chemotherapy alone or with 1 year of bevacizumab (5 
mg/kg/week equivalent). Stratification factors were nodal status, selected 
chemotherapy, hormone receptor status, and type of surgery. The primary end point 
was invasive disease-free survival (IDFS; previously reported). Secondary outcome 
measures included overall survival (OS) and safety.  
Results: After 56 months’ median follow-up, 293 of 2591 randomized patients had 
died. There was no statistically significant difference in OS between treatment arms 
in either the total population (hazard ratio 0.93, 95% confidence interval [CI] 0.74–
1.17; P = 0.52) or pre-specified subgroups. The 5-year OS rate was 88% (95% CI 
86–90%) in both treatment arms. Updated IDFS results were consistent with the 
primary IDFS analysis. Five-year IDFS rates were 77% (95% CI 75–79%) with 
chemotherapy alone versus 80% (95% CI 77–82%) with bevacizumab. From 18 
months after first study dose to study end, new grade ≥3 adverse events occurred in 
4.6% and 4.5% of patients in the two arms, respectively.  
Conclusion: Final OS results showed no significant benefit from bevacizumab 
therapy for early TNBC. Late-onset toxicities were rare in both groups. Five-year OS 
and IDFS rates suggest that the prognosis for patients with TNBC is better than 
previously thought. 
ClinicalTrials.gov: NCT00528567 
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Key Message: Final overall survival results of the open-label randomized phase III 
BEATRICE trial showed no significant benefit from the addition of 1 year of 
bevacizumab therapy to standard adjuvant chemotherapy for triple-negative breast 
cancer. These results are consistent with the previously reported analyses of the 
primary endpoint (invasive disease-free survival).   
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introduction 
In HER2-negative breast cancer, combining bevacizumab with chemotherapy 
significantly improves progression-free survival (PFS) in the metastatic setting [1–6] 
and the pathologic complete response (pCR) rate in the neoadjuvant setting [7–11]. 
However, accumulating phase III data in the adjuvant setting in both colon and 
breast cancers have shown no benefit from adding 1 year of bevacizumab therapy to 
standard chemotherapy [12–17]. Similarly, recently published data for another anti-
angiogenic approach – vascular endothelial growth factor (VEGF) receptor tyrosine 
kinase inhibition – showed no benefit as adjuvant therapy for high-risk renal cell 
carcinoma [18]. Primary efficacy results from the BEATRICE trial in early triple-
negative breast cancer (TNBC) showed no significant difference in invasive disease-
free survival (IDFS; primary outcome measure) between adjuvant bevacizumab and 
non-bevacizumab regimens after first events in 393 (15%) of the 2591 randomized 
patients [15]. The stratified hazard ratio (HR) for IDFS was 0.87 (95% confidence 
interval [CI] 0.72–1.07; P = 0.18). Interim overall survival (OS) results at the time of 
the primary analysis were immature, with events in 107 patients (8%) in the 
chemotherapy-alone group and 93 patients (7%) in the bevacizumab-containing 
group. Here we report extended follow-up data from the pre-specified OS analysis of 
BEATRICE at 56 months’ median follow-up. 
patients and methods 
study design 
BEATRICE was an open-label international randomized phase III trial. As described 
previously [15], eligible patients had operable primary invasive breast cancer (T1b–
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T3 or T1a with ipsilateral axillary node involvement) centrally confirmed as HER2-
negative and with hormone receptor status that was either negative (total Allred 
score of 0 or 2) or low (total Allred score of 3 [intensity score 1, proportion score 2]). 
Definitive surgery (breast conserving or mastectomy) had to be completed 4–11 
weeks before randomization. Patients were aged ≥18 years with an Eastern 
Cooperative Oncology Group performance status of 0 or 1 and a left ventricular 
ejection fraction of ≥55% measured up to 3 months before randomization.  
Before randomization, investigators selected chemotherapy for each patient from a 
pre-specified suite of standard chemotherapy regimens. After surgical resection, 
eligible patients were stratified by axillary nodal status (0 versus 1–3 versus ≥4 
positive lymph nodes), selected chemotherapy (anthracycline versus taxane versus 
anthracycline and taxane), hormone receptor status (negative versus low), and type 
of surgery (breast conserving versus mastectomy). Patients were randomized to 
receive either chemotherapy followed by observation or the same chemotherapy 
combined with bevacizumab and followed by single-agent bevacizumab. Patients 
who underwent breast-conserving surgery received loco-regional adjuvant 
radiotherapy according to local guidelines. Bevacizumab was given at a dose 
equivalent to 5 mg/kg every week (15 mg/kg every 3 weeks or 10 mg/kg every 2 
weeks) with the selected chemotherapy. After completing chemotherapy, patients 
underwent clinical and laboratory assessments every 3 weeks for the first year after 
randomization. Thereafter, all patients had annual mammography and clinical review 
every 3 months for 2 years, then every 6 months for 2 years, and subsequently 
annual clinic visits coinciding with mammography. Adverse events were graded 
according to National Cancer Institute Common Terminology Criteria for Adverse 
Events (version 3.0) and recorded at every clinic visit. Safety reporting in the post-
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treatment period (from 18 months after the first dose of study drug until end of study) 
was limited to newly occurring grade ≥3 adverse events, serious adverse events, 
and adverse events of special interest.  
All patients provided written informed consent. The study was approved by the 
institutional review board at each participating center and was conducted according 
to the principles of Good Clinical Practice, the provisions of the Declaration of 
Helsinki, and other applicable local regulations.  
statistical analysis 
The primary objective was to compare IDFS in patients treated with chemotherapy 
alone versus chemotherapy plus bevacizumab. The sample size was calculated 
based on assumptions relating to the primary outcome measure (IDFS), as 
described previously [15].  
Secondary end points included OS, breast cancer-free interval, disease-free survival 
(DFS), distant DFS, and safety. The interim OS analysis and additional secondary 
end points were reported with the primary end point. The final OS analysis was 
planned to be performed after a median follow-up of approximately 5 years or after 
340 deaths, whichever occurred first. A total of 340 deaths would provide 75% power 
to detect an OS HR of 0.75 with a two-sided log-rank test at 5% alpha. 
Efficacy end points were tested using a two-sided stratified log-rank test. Kaplan-
Meier estimates were plotted by treatment group. Treatment effects were estimated 
by HRs with 95% CIs based on Cox regression models. Unstratified and stratified 
analyses (applying the stratification factors used at randomization) were performed. 
Subgroups of interest were pre-specified in the statistical analysis plan and included 
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the stratification factors as well as other disease- and patient-related prognostic 
factors. SAS (version 8.2; SAS Institute Inc., Cary, NC) was used for all statistical 
analyses. 
results 
patient population  
Between December 3, 2007, and March 8, 2010, 2591 patients were randomized; of 
these, 2559 received treatment (Supplementary Figure S1). Baseline characteristics 
and investigator-selected adjuvant chemotherapy regimens are summarized in 
Supplementary Table S1. 
efficacy 
At the time of data cutoff for the final OS analysis (June 30, 2014), the median 
duration of follow-up from randomization was 56 months in both treatment groups. 
All patients had discontinued or completed study therapy. Overall, 293 patients had 
died (86% of the 340 estimated OS events for the final analysis). Most deaths were 
from breast cancer recurrence (131 of 147 [89%] deaths in patients treated with 
chemotherapy alone, 136 of 144 [94%] deaths in bevacizumab-treated patients, and 
one of two deaths in patients who received no study therapy). Causes of death in the 
remaining patients are summarized in Supplementary Table S2.   
There was no statistically significant difference in OS between the two treatment 
groups either in the intent-to-treat population (stratified HR = 0.93, 95% CI 0.74–
1.17; log-rank P = 0.52; Figure 1) or in any of the pre-specified subgroups (Figure 2). 
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The unstratified analysis of OS showed similar results (unstratified HR = 0.94, 95% 
CI 0.75–1.18; log-rank P = 0.61).  
Results of an exploratory analysis updating IDFS at the time of this final OS analysis 
were very consistent with those of the primary analysis (Supplementary Figure S2). 
The stratified HR was 0.87 (95% CI 0.73–1.03). The 5-year IDFS rates in this 
updated exploratory analysis were 76.9% (95% CI 74.4–79.4%) with chemotherapy 
alone and 79.6% (95% CI 77.2–81.9%) with bevacizumab-containing therapy. 
At the time of data cutoff, bevacizumab therapy had been recorded after an IDFS 
event in 34 patients (2.6%) in the chemotherapy-alone arm and 13 patients (1.0%) in 
the bevacizumab-containing arm (12.6% versus 5.3%, respectively, of those with 
IDFS events). 
safety 
In the post-treatment safety reporting period there were relatively few grade ≥3 
adverse events in either arm (4.6% and 4.5% in the chemotherapy-alone and 
bevacizumab-containing arms, respectively) and no relevant differences between 
treatment arms were observed (Table 1). The only grade ≥3 adverse events 
occurring in more than two patients in either treatment group were hypertension and 
deep vein thrombosis, which occurred in 0.3% and 0.2% of patients, respectively, in 
the chemotherapy-alone group but were absent in the bevacizumab-containing 
group. The incidences of adverse events of special interest occurring from 18 
months after the first dose of study drug until the end of the study were very similar 
between the two treatment arms (Supplementary Table S3). Detailed cardiac safety 
analyses based on the final data cutoff described here will be reported separately. 
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discussion 
The final OS analysis of the BEATRICE trial after 293 deaths showed no statistically 
significant benefit from adding bevacizumab to standard adjuvant chemotherapy for 
patients with early TNBC. Results of exploratory updated analyses of IDFS were 
similar to those from the primary IDFS analysis, showing no difference between the 
treatment arms (Supplementary Table S4). No new safety signals were identified 
with long-term follow-up and the safety profile was consistent with the established 
safety profile of bevacizumab in metastatic breast cancer [19] and the primary 
analysis of the BEATRICE trial [15]. 
Since the publication of the primary results from BEATRICE, two additional phase III 
trials evaluating bevacizumab as adjuvant therapy for early breast cancer have been 
reported: the BETH trial (N = 3509) in HER2-positive disease [16] and the E5103 trial 
(N = 4994) in lymph node-positive or high-risk node-negative HER2-negative disease 
[17]. None of these three randomized phase III trials (BEATRICE, BETH, and E5103; 
combined N = 11,094) provides evidence of efficacy of bevacizumab in the post-
operative adjuvant setting. One additional trial, National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-40, evaluated adjuvant bevacizumab but uniquely in 
this trial, patients received bevacizumab with neoadjuvant chemotherapy as well as 
post-operatively. Intriguingly, final results from the NSABP B-40 trial demonstrated a 
significant OS benefit with neoadjuvant and adjuvant bevacizumab versus 
neoadjuvant chemotherapy alone, although the improvement in DFS did not reach 
statistical significance [20]. The benefit from bevacizumab was more pronounced in 
patients with hormone receptor-positive disease, whereas in other neoadjuvant trials 
(GeparQuinto, ARTemis, and S0800) [8, 9, 11, 21] and the E5103 adjuvant trial [17], 
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a greater effect was observed in patients with TNBC. Specifically in TNBC, the 
Cancer and Leukemia Group B (CALGB) 40603 (Alliance) neoadjuvant trial 
demonstrated a significantly improved pCR rate with 18 weeks of bevacizumab 
added to chemotherapy for stage II or III disease, but the effect on DFS or OS is as 
yet unknown [10]. Taken together, none of these results support the use of 
bevacizumab in the primary breast cancer setting.  
The lack of effect of bevacizumab as adjuvant therapy (in contrast to improved pCR 
rate with bevacizumab in the neoadjuvant setting or PFS benefit in the metastatic 
setting) is perhaps not surprising when considering the absence of macroscopic 
disease in patients receiving adjuvant treatment and recent results in preclinical 
models mimicking adjuvant therapy [22]. A vascular supply is required for tumor 
growth beyond a few millimeters [23, 24] and it is unclear what proportion of the 
subgroup of patients ultimately destined to relapse will have had micrometastic 
disease of this size during bevacizumab exposure in the BEATRICE trial (1 year) 
[25]. Proposed mechanisms by which VEGF blockade could influence disease 
recurrence in the adjuvant setting include prolonging the dormancy of 
micrometastatic tumor cell aggregates, preventing ‘awakening’ of dormant 
micrometastases by blocking new vessel formation, and inhibiting tumor 
dissemination [26], but there is currently no evidence to suggest that these 
postulated mechanisms translate into a clinically useful effect of adjuvant 
bevacizumab therapy for 1 year. A longer duration of adjuvant bevacizumab 
administration may be hypothesized to improve efficacy [25], especially when 
considering the transient benefit from bevacizumab seen in the two phase III trials in 
colon cancer [12, 14]. On the other hand, results from the AVANT trial [12] may be 
used to argue against indefinite use of VEGF blockade in the adjuvant setting [26]. 
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Recently published preclinical data suggest that the effect of VEGF inhibition on host 
vasculature depends not only on the class of agent (antibody versus multi-targeted 
tyrosine kinase inhibition) but also on co-administration with chemotherapy [27]. The 
researchers concluded that the benefit of an anti-angiogenic therapy can be 
improved by chemotherapy as well as the efficacy of chemotherapy being increased 
by combining with anti-angiogenic therapy (i.e. a mutual bidirectional effect). If this 
holds true in the clinical setting, better outcomes would be achieved by administering 
all of the bevacizumab in combination with a tolerable chemotherapy in the adjuvant 
setting, rather than as a single agent for most of the duration. This strategy has been 
shown to be beneficial in the metastatic setting, where the addition of capecitabine to 
maintenance bevacizumab in patients with response or stable disease following 
initial therapy with bevacizumab plus a taxane significantly improved both PFS and 
OS compared with bevacizumab alone in the randomized phase III IMELDA trial [28]. 
However, in early breast cancer this approach has been tested only in the ECOG 
5103 trial, in which bevacizumab treatment duration was limited to the duration of the 
standard chemotherapy in one of the treatment arms. There was no evidence that 
this approach was more effective, but the possibility that a longer duration of 
concomitant chemotherapy and bevacizumab could be effective remains untested in 
the adjuvant setting. However, while these may all be interesting hypotheses for 
exploration, the feasibility, likelihood of success, and priority for conducting further 
trials of bevacizumab in the adjuvant breast cancer setting are extremely low when 
considering all available data and emerging research on new strategies, such as the 
use of capecitabine in patients with residual disease after neoadjuvant therapy [29] 
or novel agents [30].  
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Although results of the BEATRICE trial do not help in identifying a targeted treatment 
option for early TNBC, they provide valuable information that may help in the design 
of future trials. Firstly, they serve to remind us that treatments demonstrating efficacy 
in the macrometastatic setting cannot simply be extrapolated to the adjuvant setting, 
which is biologically very different from the neoadjuvant and metastatic settings. 
Secondly, results from the BEATRICE trial indicate that the prognosis for patients 
with early TNBC is better than previously thought. Data from retrospective series 
suggest that most recurrences occur within 3–5 years of TNBC diagnosis [31]. 
However, after a median follow-up of 56 months in BEATRICE, the 5-year IDFS 
rates were 77% in the chemotherapy-alone arm and 80% in the chemotherapy plus 
bevacizumab arm. These event rates should inform the statistical design of future 
studies in TNBC. In addition, ongoing gene expression analyses in the pooled 
dataset from BEATRICE have already yielded fascinating preliminary results in 
relation to immune signatures [32], which may guide future research in TNBC. Thus, 
although BEATRICE failed to confirm its primary hypothesis, it has provided the first 
randomized phase III data on systemic therapy in early TNBC, as well as interesting 
translational findings, all of which will inform future trial designs in this patient 
population. 
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figure legends 
Figure 1. Final OS (intent-to-treat population). BEV, bevacizumab; CI, confidence 
interval; CT, chemotherapy; HR, hazard ratio; OS, overall survival. 
Figure 2. Subgroup analyses of final overall survival. BEV, bevacizumab; CI, 
confidence interval; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology 
Group performance status; ER, estrogen receptor; HR, hazard ratio; PgR, 
progesterone receptor. 
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Supplementary figure legends 
Supplementary Figure S1. CONSORT flow diagram.  
*Violation of at least one inclusion or exclusion criterion.  
Supplementary Figure S2. Updated IDFS results (intent-to-treat population, 
exploratory analysis after a median follow-up of 56 months). BEV, bevacizumab; CI, 
confidence interval; CT, chemotherapy; HR, hazard ratio; IDFS, invasive disease-
free survival. 
 
Table 1. Adverse events by treatment phase and study arm (safety population, all patients who received at least one dose of 
study drug) 
Adverse event From first dose of study drug to 18 months 
after first dose 
From 18 months after first dose of study 
drug to end of studya 
 Chemotherapy alone 
(N = 1271) 
Chemotherapy + 
bevacizumab 
(N = 1288) 
Chemotherapy alone 
(N = 1271) 
Chemotherapy + 
bevacizumab 
(N = 1288) 
Any adverse event, N (%) 1252 (98.5) 1274 (98.9) 173 (13.6) 200 (15.5) 
Grade ≥ 3 adverse event, N (%) 722 (56.8) 924 (71.7) 58 (4.6) 58 (4.5) 
Grade 5 adverse event, N (%) 3 (0.2) 4 (0.3) 1 (0.1)b 1 (0.1)c 
Grade ≥ 3 adverse event of 
special interest for bevacizumab, 
N (%) 
499 (39.3) 687 (53.3) 9 (0.7) 9 (0.7) 
Any serious adverse event, N (%) 250 (19.7) 379 (29.4) 48 (3.8) 45 (3.5) 
aNone of the patients was receiving study therapy during this period; consequently there were no adverse events leading to 
discontinuation of study therapy. 
bHypoxic-ischemic encephalopathy. 
cCerebrovascular accident. 
 
Supplementary Table S1. Baseline characteristics and planned adjuvant 
chemotherapy choice (ITT population) 
Characteristic Chemotherapy alone 
(N = 1290) 
Chemotherapy + 
bevacizumab 
(N = 1301) 
Age, years, N (%)   
<40 253 (19.6) 231 (17.8) 
40–64 916 (71.0) 952 (73.2) 
≥65 121 (9.4) 118 (9.1) 
Menopausal status, N (%)   
Premenopausal 665 (51.6) 676 (52.0) 
Postmenopausal 625 (48.4) 625 (48.0) 
ECOG performance status, N 
(%) 
  
0 1186 (91.9) 1202 (92.4) 
1 94 (7.3) 98 (7.5) 
2 1 (<0.1) 0 
Missing 9 (0.7) 1 (<0.1) 
Geographic region, N (%)   
USA, Australia, Western 
Europe 
792 (61.4) 783 (60.2) 
Eastern Europe, Greece, 
Israel 
160 (12.4) 148 (11.4) 
South and Central America 37 (2.9) 22 (1.7) 
Asia, New Zealand 301 (23.3) 348 (26.7) 
Race, N (%)   
White 968 (75.0) 932 (71.6) 
Asian 280 (21.7) 333 (25.6) 
Black 32 (2.5) 29 (2.2) 
Other 10 (0.8) 7 (0.5) 
Tumor size, cm (tumor stage), 
N (%) 
  
>0–<2 (T1)  457 (35.4) 482 (37.0) 
2–<5 (T2)  759 (58.8) 755 (58.0) 
≥5 (T3)  71 (5.5) 61 (4.7) 
Missing  3 (0.2) 3 (0.2) 
AJCC stage I, N (%) 388 (30.1) 382 (29.4) 
Hormone receptor statusa, N 
(%) 
  
ER and PgR negative  1224 (94.9) 1229 (94.5) 
ER and/or PgR low  66 (5.1) 72 (5.5) 
Positive axillary nodesa, N (%)   
0 814 (63.1) 824 (63.3) 
1–3 326 (25.3) 322 (24.8) 
≥4 150 (11.6) 155 (11.9) 
Ductal/invasive histology, N 
(%) 
1183 (91.7) 1209 (92.9) 
Grade 3 tumor, N (%) 895 (69.4) 912 (70.1) 
Type of surgerya, N (%)   
Breast conserving  817 (63.3) 827 (63.6) 
Mastectomy 473 (36.7) 474 (36.4) 
Planned adjuvant 
chemotherapya, N (%) 
  
Anthracycline  468 (36.3) 479 (36.8) 
Anthracycline and taxane  756 (58.6) 752 (57.8) 
Taxane  66 (5.1) 70 (5.4) 
Hormonal therapy, N (%) 7 (0.5) 4 (0.3) 
Radiotherapy, N (%) 953 (73.9) 952 (73.2) 
aStratification factor (data as recorded in interactive voice-response system). 
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative 
Oncology Group; ER, estrogen receptor; ITT, intent to treat; PgR, progesterone 
receptor. 
 
Supplementary Table S2. Causes of death other than breast cancer recurrence 
(safety population, N = 2559) 
Cause of death, no. of 
patients 
Chemotherapy alone 
(N = 1271) 
Chemotherapy + 
bevacizumab (N = 1288) 
Total 16 8 
Cardiac failure 1 0 
Coronary artery disease 0 1 
Cerebral hemorrhage 1 0 
Cerebrovascular accident 0 1 
Hypoxic-ischemic 
encephalopathy 
1 0 
Sepsis 0 1 
Neutropenic sepsis 1 0 
Septic shock 1 0 
Shock 1 0 
Varicella zoster 
pneumonia 
1 0 
Multi-organ failure 0 1 
Death (not otherwise 
specified) 
1 1 
Metastasisa 1 0 
Brain neoplasm 1 0 
Metastatic malignant 
melanoma 
2 0 
Pancreatic carcinoma 2 0 
Acute myeloid leukemia 0 1 
Bronchial carcinoma 0 1 
Gastric cancer 0 1 
Lung neoplasm malignant 1 0 
Pancreatic carcinoma 
metastatic 
1 0 
aNot confirmed as metastatic breast cancer. 
 
Supplementary Table S3. Grade ≥3 adverse events of special interest by 
treatment arm occurring between 18 months after the first dose of study drug 
and the end of the study 
Adverse event of special 
interest 
Chemotherapy alone 
(N = 1271) 
Chemotherapy + 
bevacizumab 
(N = 1288) 
Any event, N (%) 9 (0.7) 9 (0.7) 
Arterial thromboembolic 
event, N (%) 
1 (0.1)a 5 (0.4)b 
Venous thromboembolic 
event, N (%) 
3 (0.2)c 0 
Bleeding, N (%) 1 (0.1)d 3 (0.2)e 
Congestive heart failure, N 
(%) 
0 1 (0.1)f 
Hypertension, N (%) 4 (0.3)g 0 
Proteinuria, N (%) 0 0 
Wound-healing complication, 
N (%) 
0 2 (0.2)h 
RPLS, N (%) 0 0 
Gastrointestinal perforation, 
N (%) 
0 0 
Fistula/abscess, N (%) 0 0 
Febrile neutropenia, N (%) 0 0 
aGrade 3 myocardial infarction. 
bGrade 3 myocardial infarction (N = 1), grade 4 myocardial infarction (N = 1), 
grade 4 acute myocardial infarction (N = 1), grade 5 cerebrovascular accident (N 
= 1; the same event is also reported within the category ‘Bleeding’), grade 3 
transient ischemic attack (N = 1). 
cGrade 3 deep vein thrombosis (N = 3). 
dGrade 3 dysfunctional uterine bleeding. 
eGrade 5 cerebrovascular accident (N = 1; the same event is also reported within 
the category ‘Arterial thromboembolic event’), grade 2/3 diverticulitis intestinal 
hemorrhagic (N = 1; repeated grade 2 and one grade 3 episode, attributed to 
ongoing colonic diverticulitis), grade 4 hematoma (N = 1). 
fGrade 3 cardiac failure congestive. 
gGrade 3 hypertension (N = 4)  
hGrade 3 wound caused by a traffic accident (N = 1), grade 3 wound abscess 
(N = 1). 
In each patient, the adverse event occurred before any reported IDFS event, or 
in the case of the grade 5 cerebrovascular event, was itself the IDFS event. 
IDFS, invasive disease-free survival; RPLS, reversible posterior 
leukoencephalopathy syndrome. 
 
Supplementary Table S4. Summary of results 
End point Primary analysis (cutoff: February 29, 2012) 
[15] 
OS analysis (cutoff: June 30, 2014) 
 Chemotherapy alone 
(N = 1290) 
Chemotherapy + 
bevacizumab 
(N = 1301) 
Chemotherapy alone 
(N = 1290) 
Chemotherapy + 
bevacizumab 
(N = 1301) 
Median duration of follow-up, 
months 
31.5 32.0 56.0 56.0 
IDFS  Primary Exploratory 
Events, N (%)  205 (15.9) 188 (14.5) 270 (20.9) 244 (18.8) 
Stratified HR (95% CI)  0.87 (0.72–1.07) 0.87 (0.73–1.03) 
Log-rank P value  0.18 0.11 
3-year IDFS rate, % (95% CI) 82.7 (80.5–85.0) 83.7 (81.4–86.0) 82.8 (80.7–84.9) 84.6 (82.6–86.6) 
OS Interim  Final 
Events, N (%)  107 (8.3) 93 (7.1) 149 (11.6) 144 (11.1) 
Stratified HR (95% CI) 0.84 (0.64–1.12) 0.93 (0.74–1.17) 
Log-rank P value  0.23 0.52 
CI, confidence interval; HR, hazard ratio; IDFS, invasive disease-free survival; OS, overall survival. 
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